Bressler, Karen
July 1997
Self;Jul97, Vol. 19 Issue 7, p34
Reports that dermatologists in the United States are recommending that persons use Allergan Incorporated's Botox, a freeze-dried form of the botulism toxin, as an alternative way to remove unwanted facial lines and wrinkles. How the substance should be administered; Therapeutic use of the toxin.


Related Articles

  • Botox Study: Help on Migraines in Chronic Cases. Reed, Vita // Orange County Business Journal;5/7/2012, Vol. 35 Issue 19, p92 

    The article focuses on a study which shows that botulinum toxin A, an active ingredient in the Botox drug from Allergan Inc., might be helpful for people with chronic migraine headaches.

  • THE BOTOX BOOM. Noonan, David; Adler, Jerry; Springen, Karen; Raymond, Joan; Figueroa, Ana; Skipp, Catharine; Scelfo, Julie; Smalley, Suzanne // Newsweek;5/13/2002, Vol. 139 Issue 19, p50 

    Reports on Botox, a drug used to relieve the appearance of wrinkles in the face. How Botox is made from botulinum toxin type A, which causes food poisoning; Approval of Botox by the U.S. Food and Drug Administration; Potential of the drug to be very lucrative for Allergan, a California...

  • Promise seen for Botox in studies focusing on headache treatment. PEDERSEN, AMANDA // Biomedical Business & Technology;Oct2008, Vol. 31 Issue 10, p35 

    The article talks about the pursuit by Allergan of botulinum toxin type A or Botox therapy to treat headaches and migraines. Allergan said it has completed a top-line analysis of its two Phase III trials exploring the use of Botox for the prophylactic treatment of headache in adults suffering...

  • Allergan, Government Settle Botox Claims Case.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p94 

    The article reports on the Allergan Inc.'s 600 million dollar pay for the resolution of charges for false Botox claims.

  • Allergan Reports 1st Qtr 2012 Operating Results.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article informs that Allergan Inc. has released its financial results for the 1st quarter of 2012 and the dividend of 0.05 dollar per share. It further informs that the company has submitted an application with Health Canada regarding the approval of BOTOX for the treatment of overactive...

  • Attorney General Koster recovers $1.6 million from pharmaceutical company for illegal use of Botox.  // Southern Illinois Labor Tribune;11/4/2010, Vol. 74 Issue 14, p9 

    The article reports that attorney-general Chris Koster has recovered 1.6 million dollars from Allergan Inc. and Allergan USA Inc. as part of the national settlement arising from the pharmaceutical company's illegal use of the drug Botox.

  • Botox OK'd for migraines.  // Nurse Practitioners Prescribing Reference;Winter2010/2011, Vol. 17 Issue 4, pA.18 

    The article reports on the gained indication of the Botox or the onabotulinumtoxin A from Allergan Inc. for the prophylactic treatment of headaches in adults with chronic migraine.

  • Allergan heeds FDA warnings, revises Botox Web site content.  // Dermatology Times;Oct2001, Vol. 22 Issue 10, p62 

    Reports the revision of botulinum toxin Web site by Allergan in the United States. Promotion of Botox neuromuscular treatment to doctors; Failure of promotional materials to inform doctors on the risks associated with Botox; Plans to include labeling excerpts about Botox contraindications and...

  • Allergan Celebrates 25 Years of Botox With Campaign. DiMartino, Mediha // Orange County Business Journal;5/19/2014, Vol. 37 Issue 20, p65 

    The article focuses on business-related issues in California in 2014 including the celebration of Irvine-based pharmaceutical company Allergan Inc. of its 25th anniversary of Botox, the launch of a marketing campaign from the Trinity University, and the branding campaign from Yokohama Tire Corp.

  • Allergan: Botox to the bladder is nothing to frown about.  // PharmaWatch: CNS;Oct2011, Vol. 10 Issue 10, p4 

    The article focuses on the issue involving Botox, an Allergan Inc.'s drug used to treat neurogenic overactive bladder in the U.S. It mentions that the drug is the first to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of neurogenic overactive bladder in patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics